1 Min Read
Dec 8 (Reuters) - Amicus Therapeutics Inc
* Amicus Therapeutics announces positive preliminary data from phase 1/2 study of novel treatment paradigm for pompe disease Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.